U.S. National Institute of Health www.cancer.gov National Cancer Institute
Skip Navigation
National Cancer Institute
Physical Sciences in Oncology Network Investigators Meeting


Pathology Boot Camp Brief Description
Kelly Bethel, MD
The Scripps Clinic
The Scripps Research Institute PS-OC

An experiential pathology diagnostic workshop conducted in small groups at a ten-headed microscope, with discussion and demonstration of the process of diagnosing cancer in the clinical setting. Examples of various tumors will be microscopically reviewed, with discussion of basic histologic features, pitfalls and challenges in clinical pathologic diagnosis, and testing limitations imposed by tissue scarcity.  Among the tumors reviewed will be cases that will be discussed at the Tumor Board demonstration later that morning, so the participants will be prepared to experience and/or participate in the subsequent Tumor Board discussions from the perspective of the diagnosing pathologist.  Three 45 minute sessions will be offered, each of which will cover essentially the same material.

An Overview of the PS-OC Bioresource Core Facility (PBCF)
Yvonne A. Reid, PhD
Manager, Scientist, Cell Biology Program, ATCC
Program Manager, PBCF

The PBCF, located at ATCC, is a new initiative sponsored by the NCI’s Office of Physical Sciences-Oncology to support research and promote collaborations within the PS-OC Network. The goal of the PBCF is to provide the PS-OC Network Investigators with consistent, reliable and well-characterized biomaterial (cell lines, primary cells, DNA, RNA and protein) and associated media, reagents and SOPs. This tutorial will highlight some of the resources available to the PS-OC Network through the PBCF.

Applications of Nanobiotechnolgy
Michael L. Shuler, PhD
Cornell University
Cornell University PS-OC The application of the techniques of nanotechnology to biological systems offer the possibility of unprecedented control over the spatial and temperal environment placed on a biological system.  As a consequence biological systems can be probed in novel ways allowing relatively high throughput, facilitating comprehensive data collection to address fundamental, biological issues.  We will briefly review basic techniques, and then focus on example applications of nanobiotechnology to important biological questions.

An overview of blood coagulation and cancer metastasis
Owen McCarty, PhD
Oregon Health Science University
The Scripps Research Institute PS-OC

Cancer metastasis is the process whereby cancer cells separate from the primary tumor mass, enter the vascular or lymphatic circulation, exit into a new tissue, and colonize the invaded microenvironment. During their transit through the circulation, cancer cells are exposed to fluid mechanical forces, plasma proteins, and peripheral blood cells, all of which may affect their survival and extravasation from the vasculature. Metastatic cancer has long been linked to coagulopathies such as thromboembolism, a leading cause of death in cancer patients. This tutorial will give an overview on the relationship between cancer metastasis and the pathways of thrombosis and hemostasis.

Show Case Tumor Board
Medical Oncology; Jorge Nieva, MD, Billings Clinic
Thoracic Medical Oncology; Ludmila Bazhenova, MD, UC San Diego
Anatomical Pathology; Kelly Bethel, MD, Scripps Clinic
Radiation Oncology; Arno Mundt, MD, UC San Diego
Surgery; Randy Schaffer, MD, Scripps Clinic
The Scripps Research Institute PS-OC

The PS-OC initiative is intended to encourage cross-disciplinary interactions to foster clinically useful advances in cancer diagnostics and therapeutics.  A challenge to successful cross disciplinary research is failure to understand the language and approach of collaborators with different training.  This session will focus on common clinical scenarios in oncology using the format of a hospital “tumor board”, as would occur at any academic or community cancer center.  Patient cases will be presented in a manner to encourage interactions between clinicians and quantitative scientists.  Audience will have an opportunity to understand the major decision points for therapeutics, together with the limitations of present day technology. Common problems in oncology will be addressed including diagnostic challenges in the modern era of small biopsy samples, uncertainty in delivery of adjuvant therapy with a description of the currently used statistical models, surveillance strategies for recurrent disease in association with the inherent fallacy of the “early” detection of an incurable stage.  A clinical case will review limitations of local therapies in patients with compromised end organ reserve and challenges in obtaining useful molecular information as technology has moved in the direction of smaller biopsy specimens.

Second Annual Physical Sciences in Oncology Meeting
April 10 - 12, 2011
Hyatt Regency La Jolla at Aventine